Brief: Essex Bio-Technology announces approval to commercialise Tobramycin eye drops in China
June 13 (Reuters) - Essex Bio-technology Ltd 1061.HK :
* Announces approval to commercialise preservative-free
single-dose Tobramycin eye drops in China
* Approved product is expected to be launched in market at
or around end of 2017
Source text for Eikon: urn:newsml:reuters.com:*:nHKSblP8w2
Further company coverage: 1061.HK
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Essex Bio-Technology
See all newsHong Kong's Essex Bio-Technology H1 revenue falls
Brief: Essex Bio-Technology Posts HY Profit Of HK$110.7 MLN
Brief: Essex Bio-Technology Expects 10% Revenue And 30% Profit Decrease For HY
Brief: Shanghai Henlius Biotech Says Phase 3 Study Of HLX04-O For WAMD Meets Primary Endpoint
Brief: Essex Bio-Technology Posts Final Dividend Of HK$0.07 Per Share